银屑病关节炎中白细胞介素-23 信号通路的病理生理学和抑制：分子见解。
Pathophysiology and inhibition of IL-23 signaling in psoriatic arthritis: A molecular insight.
机构信息
Department of Internal Medicine, Division of Rheumatology, Allergy and Clinical Immunology, University of California at Davis, CA, USA.
Department of Biochemistry and Microbiology, Ghent University, Technologiepark 927, Ghent 9052, Belgium; VIB Center for Inflammation Research, Technologiepark 927, Ghent 9052, Belgium.
出版信息
Clin Immunol. 2019 Sep;206:15-22. doi: 10.1016/j.clim.2018.09.002. Epub 2018 Sep 6.
Abstract
Psoriatic arthritis (PsA) is a chronic inflammatory arthritis of unknown etiology, and currently the cellular and molecular interactions that dictate its pathogenesis remain elusive. A role of the interleukin-23 (IL-23)/IL-23R (IL-23 receptor) interaction in the development of psoriasis and PsA is well established. As IL-23 regulates the differentiation and activation of innate and adaptive immunity, it pertains to a very complex pathophysiology involving a plethora of effectors and transducers. In this review, we will discuss recent advances on the cellular and molecular pathophysiological mechanisms that regulate the initiation and progression of PsA as well as new therapeutic approaches for IL-23/IL-23R targeted therapeutics.
摘要
银屑病关节炎（PsA）是一种病因不明的慢性炎症性关节炎，目前尚不清楚决定其发病机制的细胞和分子相互作用。白细胞介素 23（IL-23）/IL-23 受体（IL-23R）相互作用在银屑病和 PsA 的发展中的作用已得到充分证实。由于 IL-23 调节先天和适应性免疫的分化和激活，因此它与涉及众多效应物和转导物的非常复杂的病理生理学有关。在这篇综述中，我们将讨论调节 PsA 起始和进展的细胞和分子病理生理机制的最新进展，以及针对 IL-23/IL-23R 的新型治疗方法。
相似文献
1
Pathophysiology and inhibition of IL-23 signaling in psoriatic arthritis: A molecular insight.银屑病关节炎中白细胞介素-23 信号通路的病理生理学和抑制：分子见解。
Clin Immunol. 2019 Sep;206:15-22. doi: 10.1016/j.clim.2018.09.002. Epub 2018 Sep 6.
2
Interleukin-12 and interleukin-23 inhibition in psoriatic arthritis.银屑病关节炎中白细胞介素-12和白细胞介素-23的抑制作用
Clin Exp Rheumatol. 2015 Sep-Oct;33(5 Suppl 93):S115-8. Epub 2015 Oct 15.
3
Biological and synthetic target DMARDs in psoriatic arthritis.生物制剂和合成靶向 DMARDs 在银屑病关节炎中的应用。
Pharmacol Res. 2019 Nov;149:104473. doi: 10.1016/j.phrs.2019.104473. Epub 2019 Oct 1.
4
Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy.优特克单抗治疗克罗恩病：设计、研发及在治疗中的潜在地位
Drug Des Devel Ther. 2016 Nov 11;10:3685-3698. doi: 10.2147/DDDT.S102141. eCollection 2016.
5
Treatment of psoriasis and psoriatic arthritis.治疗银屑病和银屑病关节炎。
BioDrugs. 2013 Jan;27 Suppl 1:3-12. doi: 10.1007/BF03325637.
6
Remission, low disease activity and improvement of pain and function in psoriatic arthritis patients treated with IL-12/23 and IL-17 inhibitors. A multicenter prospective study.接受 IL-12/23 和 IL-17 抑制剂治疗的银屑病关节炎患者的缓解、低疾病活动度以及疼痛和功能的改善。一项多中心前瞻性研究。
Reumatismo. 2020 Apr 10;72(1):52-59. doi: 10.4081/reumatismo.2020.1266.
7
The safety of ustekinumab for the treatment of psoriatic arthritis.优特克单抗治疗银屑病关节炎的安全性。
Expert Opin Drug Saf. 2017 Jun;16(6):733-742. doi: 10.1080/14740338.2017.1323864. Epub 2017 May 9.
8
A review of ustekinumab in the treatment of psoriatic arthritis.优特克单抗治疗银屑病关节炎的综述。
Immunotherapy. 2018 Apr;10(5):361-372. doi: 10.2217/imt-2017-0149. Epub 2018 Feb 14.
9
Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.司库奇尤单抗用于治疗中度至重度斑块状银屑病和银屑病关节炎的成人患者。
Expert Rev Clin Pharmacol. 2016 Nov;9(11):1423-1433. doi: 10.1080/17512433.2016.1242409. Epub 2016 Oct 11.
10
The Psoriasis Treatment Pipeline: An Overview and Update.银屑病治疗领域的进展：概述与更新。
Dermatol Clin. 2024 Jul;42(3):365-375. doi: 10.1016/j.det.2024.02.006. Epub 2024 Mar 23.
引用本文的文献
1
Management of Chronic Plaque Psoriasis through Panchkarma: A case report.通过五种疗法管理慢性斑块状银屑病：一例报告。
J Ayurveda Integr Med. 2025 Jan-Feb;16(1):101072. doi: 10.1016/j.jaim.2024.101072. Epub 2025 Jan 17.
2
Efficacy and Safety of Risankizumab in Patients with Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.司库奇尤单抗治疗银屑病关节炎患者的疗效和安全性：一项随机对照试验的系统评价和荟萃分析
Rheumatol Ther. 2024 Apr;11(2):227-237. doi: 10.1007/s40744-024-00638-5. Epub 2024 Feb 1.
3
Osteoarthritis versus psoriasis arthritis: Physiopathology, cellular signaling, and therapeutic strategies.骨关节炎与银屑病关节炎：病理生理学、细胞信号传导及治疗策略。
Genes Dis. 2023 Jun 19;11(3):100986. doi: 10.1016/j.gendis.2023.04.021. eCollection 2024 May.
4
Structures of complete extracellular receptor assemblies mediated by IL-12 and IL-23.由 IL-12 和 IL-23 介导的完整细胞外受体组装体的结构。
Nat Struct Mol Biol. 2024 Apr;31(4):591-597. doi: 10.1038/s41594-023-01190-6. Epub 2024 Jan 29.
5
Axial Spondyloarthritis: Reshape the Future-From the "2022 GISEA International Symposium".轴性脊柱关节炎：重塑未来——源自“2022年GISEA国际研讨会”
J Clin Med. 2022 Dec 19;11(24):7537. doi: 10.3390/jcm11247537.
6
Structural basis of activation and antagonism of receptor signaling mediated by interleukin-27.白细胞介素-27 介导的受体信号转导的激活和拮抗作用的结构基础。
Cell Rep. 2022 Oct 18;41(3):111490. doi: 10.1016/j.celrep.2022.111490.
7
Tildrakizumab: Successful Response in Two Patients With Psoriatic Arthritis.替拉珠单抗：两名银屑病关节炎患者的成功治疗反应
Dermatol Pract Concept. 2022 Apr 1;12(2):e2022049. doi: 10.5826/dpc.1202a49. eCollection 2022 May.
8
IL-23 orchestrating immune cell activation in arthritis.IL-23 调控关节炎中的免疫细胞激活。
Rheumatology (Oxford). 2021 Oct 19;60(Suppl 4):iv4-iv15. doi: 10.1093/rheumatology/keab266.
9
Cell-penetrating Alphabody protein scaffolds for intracellular drug targeting.穿透细胞的阿尔法体蛋白支架用于细胞内药物靶向。
Sci Adv. 2021 Mar 26;7(13). doi: 10.1126/sciadv.abe1682. Print 2021 Mar.
10
Lack of evidence for expression and function of IL-39 in human immune cells.缺乏人免疫细胞中 IL-39 表达和功能的证据。
PLoS One. 2020 Dec 1;15(12):e0242329. doi: 10.1371/journal.pone.0242329. eCollection 2020.
本文引用的文献
1
A Macrophage Colony-Stimulating-Factor-Producing γδ T Cell Subset Prevents Malarial Parasitemic Recurrence.产生巨噬细胞集落刺激因子的 γδ T 细胞亚群可预防疟疾寄生虫复发。
Immunity. 2018 Feb 20;48(2):350-363.e7. doi: 10.1016/j.immuni.2018.01.009. Epub 2018 Feb 6.
2
Structural Activation of Pro-inflammatory Human Cytokine IL-23 by Cognate IL-23 Receptor Enables Recruitment of the Shared Receptor IL-12Rβ1.结构激活人促炎细胞因子 IL-23 通过同源性 IL-23 受体使共享受体 IL-12Rβ1 得以募集。
Immunity. 2018 Jan 16;48(1):45-58.e6. doi: 10.1016/j.immuni.2017.12.008. Epub 2017 Dec 26.
3
LMO4 Is a Disease-Provocative Transcription Coregulator Activated by IL-23 in Psoriatic Keratinocytes.LMO4 是一种疾病诱发的转录共激活因子，可被银屑病角质形成细胞中的 IL-23 激活。
J Invest Dermatol. 2018 May;138(5):1078-1087. doi: 10.1016/j.jid.2017.12.010. Epub 2017 Dec 16.
4
Protein engineering of the chemokine CCL20 prevents psoriasiform dermatitis in an IL-23-dependent murine model.趋化因子 CCL20 的蛋白质工程可预防依赖于 IL-23 的小鼠银屑病样皮炎。
Proc Natl Acad Sci U S A. 2017 Nov 21;114(47):12460-12465. doi: 10.1073/pnas.1704958114. Epub 2017 Nov 6.
5
Neutralization of Human Interleukin 23 by Multivalent Nanobodies Explained by the Structure of Cytokine-Nanobody Complex.细胞因子-纳米抗体复合物结构解释多价纳米抗体对人白细胞介素23的中和作用
Front Immunol. 2017 Aug 21;8:884. doi: 10.3389/fimmu.2017.00884. eCollection 2017.
6
Guselkumab: First Global Approval.古塞奇尤单抗：全球首次获批。
Drugs. 2017 Sep;77(13):1487-1492. doi: 10.1007/s40265-017-0800-7.
7
Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.替西单抗与安慰剂或依那西普治疗慢性斑块型银屑病（reSURFACE 1 和 reSURFACE 2）：两项随机对照、3 期临床试验的结果。
Lancet. 2017 Jul 15;390(10091):276-288. doi: 10.1016/S0140-6736(17)31279-5. Epub 2017 Jun 6.
8
Nrf2 Promotes Keratinocyte Proliferation in Psoriasis through Up-Regulation of Keratin 6, Keratin 16, and Keratin 17.Nrf2 通过上调角蛋白 6、角蛋白 16 和角蛋白 17 促进银屑病角质形成细胞增殖。
J Invest Dermatol. 2017 Oct;137(10):2168-2176. doi: 10.1016/j.jid.2017.05.015. Epub 2017 May 30.
9
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.利纳西珠单抗与乌司奴单抗治疗中重度斑块状银屑病的疗效比较。
N Engl J Med. 2017 Apr 20;376(16):1551-1560. doi: 10.1056/NEJMoa1607017.
10
Psoriatic Arthritis.银屑病关节炎
N Engl J Med. 2017 Mar 9;376(10):957-970. doi: 10.1056/NEJMra1505557.
Zotero 插件